Search

Your search keyword '"Christensen, Jacob Haaber"' showing total 151 results
Start Over Author "Christensen, Jacob Haaber"
151 results on '"Christensen, Jacob Haaber"'

1. Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study

Author

Linton, Kim M, Vitolo, Umberto, Jurczak, Wojciech, Lugtenburg, Pieternella J, Gyan, Emmanuel, Sureda, Anna, Christensen, Jacob Haaber, Hess, Brian, Tilly, Hervé, Cordoba, Raul, Lewis, David John, Okada, Craig, Hutchings, Martin, Clausen, Michael Roost, Sancho, Juan-Manuel, Cochrane, Tara, Leppä, Sirpa, Chamuleau, Martine E D, Gernhardt, Diana, Altıntaş, Işıl, Liu, Yan, Ahmadi, Tahamtan, Dinh, Minh H, Hoehn, Daniela, Favaro, Elena, Elliott, Brian, Thieblemont, Catherine, and Vose, Julie M

Published
2024
Full Text
View/download PDF

3. Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory mantle cell lymphoma (CITADEL-205): a phase 2 study

Author

Zinzani, Pier Luigi, Trněný, Marek, Ribrag, Vincent, Zilioli, Vittorio Ruggero, Walewski, Jan, Christensen, Jacob Haaber, Delwail, Vincent, Rodriguez, Guillermo, Venugopal, Parameswaran, Coleman, Morton, Dartigeas, Caroline, Patti, Caterina, Pane, Fabrizio, Jurczak, Wojciech, Taszner, Michal, Paneesha, Shankara, Zheng, Fred, DeMarini, Douglas J., Jiang, Wei, Gilmartin, Aidan, and Mehta, Amitkumar

Published
2023
Full Text
View/download PDF

4. Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2

Author

Savage, Kerry J., Horwitz, Steven M., Advani, Ranjana, Christensen, Jacob Haaber, Domingo-Domenech, Eva, Rossi, Giuseppe, Morschhauser, Franck, Alpdogan, Onder, Suh, Cheolwon, Tobinai, Kensei, Shustov, Andrei, Trneny, Marek, Yuen, Sam, Zinzani, Pier Luigi, Trümper, Lorenz, Ilidge, Tim, O’Connor, Owen A., Pro, Barbara, Miao, Harry, Bunn, Veronica, Fenton, Keenan, Fanale, Michelle, Puhlmann, Markus, and Iyer, Swaminathan

Published
2022
Full Text
View/download PDF

5. Machine Learning-Based Survival Prediction Models for Progression-Free and Overall Survival in Advanced-Stage Hodgkin Lymphoma

Author

Jorgensen, Rasmus Rask Kragh, Bergstroem, Fanny, Eloranta, Sandra, Severinsen, Marianne Tang, Smeland, Knut Bjoro, Fossa, Alexander, Christensen, Jacob Haaber, Hutchings, Martin, Bo Dahl-Sorensen, Rasmus, Kamper, Peter, Glimelius, Ingrid, Smedby, Karin, Parsons, Susan, Rodday, Angie Mae, Maurer, Matthew, Evens, Andrew, El-Galaly, Tarec, Jakobsen, Lasse Hjort, Jorgensen, Rasmus Rask Kragh, Bergstroem, Fanny, Eloranta, Sandra, Severinsen, Marianne Tang, Smeland, Knut Bjoro, Fossa, Alexander, Christensen, Jacob Haaber, Hutchings, Martin, Bo Dahl-Sorensen, Rasmus, Kamper, Peter, Glimelius, Ingrid, Smedby, Karin, Parsons, Susan, Rodday, Angie Mae, Maurer, Matthew, Evens, Andrew, El-Galaly, Tarec, and Jakobsen, Lasse Hjort

Abstract

Purpose Patients diagnosed with advanced-stage Hodgkin lymphoma (aHL) have historically been risk-stratified using the International Prognostic Score (IPS). This study investigated if a machine learning (ML) approach could outperform existing models when it comes to predicting overall survival (OS) and progression-free survival (PFS). Patients and Methods This study used patient data from the Danish National Lymphoma Register for model development (development cohort). The ML model was developed using stacking, which combines several predictive survival models (Cox proportional hazard, flexible parametric model, IPS, principal component, penalized regression) into a single model, and was compared with two versions of IPS (IPS-3 and IPS-7) and the newly developed aHL international prognostic index (A-HIPI). Internal model validation was performed using nested cross-validation, and external validation was performed using patient data from the Swedish Lymphoma Register and Cancer Registry of Norway (validation cohort). Results In total, 707 and 760 patients with aHL were included in the development and validation cohorts, respectively. Examining model performance for OS in the development cohort, the concordance index (C-index) for the ML model, IPS-7, IPS-3, and A-HIPI was found to be 0.789, 0.608, 0.650, and 0.768, respectively. The corresponding estimates in the validation cohort were 0.749, 0.700, 0.663, and 0.741. For PFS, the ML model achieved the highest C-index in both cohorts (0.665 in the development cohort and 0.691 in the validation cohort). The time-varying AUCs for both the ML model and the A-HIPI were consistently higher in both cohorts compared with the IPS models within the first 5 years after diagnosis. ConclusionT he new prognostic model for aHL on the basis of ML techniques demonstrated a substantial improvement compared with the IPS models, but yielded a limited improvement in predictive performance compared with the A-HIPI.

Published
2024
Full Text
View/download PDF

6. Pulmonary diseases in patients with classical Hodgkin lymphoma relative to a matched background population: A Danish national cohort study.

Author

Vandtved, Julie Haugaard, Øvlisen, Andreas Kiesbye, Baech, Joachim, Weinrich, Ulla Møller, Severinsen, Marianne Tang, Maksten, Eva Futtrup, Jakobsen, Lasse Hjort, Glimelius, Ingrid, Kamper, Peter, Hutchings, Martin, Specht, Lena, Dahl‐Sørensen, Rasmus, Christensen, Jacob Haaber, and El‐Galaly, Tarec C.

Subjects
OBSTRUCTIVE lung diseases, INTERSTITIAL lung diseases, PULMONARY fibrosis, CHRONIC obstructive pulmonary disease, LUNG diseases
Abstract

Summary: Late toxicities can impact survivorship in patients with classical Hodgkin lymphoma (cHL) with pulmonary toxicity after bleomycin‐containing chemotherapy being a concern. The incidence of pulmonary diseases was examined in this Danish population‐based study. A total of 1474 adult patients with cHL treated with ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine) or BEACOPP (bleomycin, vincristine, etoposide, doxorubicin, cyclophosphamide, procarbazine and prednisone) between 2000 and 2018 were included along with 7370 age‐ and sex‐matched comparators from the background population. Median follow‐up was 8.6 years for the patients. Patients with cHL had increased risk of incident pulmonary diseases (HR 2.91 [95% CI 2.30–3.68]), with a 10‐year cumulative risk of 7.4% versus 2.9% for comparators. Excess risks were observed for interstitial lung diseases (HR 15.84 [95% CI 9.35–26.84]) and chronic obstructive pulmonary disease (HR 1.99 [95% CI 1.43–2.76]), with a 10‐year cumulative risk of 4.1% and 3.5% respectively for patients. No excess risk was observed for asthma (HR 0.82 [95% CI 0.43–1.56]). Risk factors for interstitial lung diseases were age ≥60 years, the presence of B‐symptoms and low albumin. These findings document a significant burden of pulmonary diseases among patients with cHL and emphasize the importance of diagnostic work‐up of pulmonary symptoms. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

7. Deep and Durable Responses with Epcoritamab SC Monotherapy in Patients with Relapsed or Refractory Follicular Lymphoma: Data from the Epcore NHL-1 Follicular Lymphoma Dose-Expansion Cohort

Author

Linton, Kim M, primary, Jurczak, Wojciech, additional, Lugtenburg, Pieternella J., additional, Gyan, Emmanuel, additional, Sureda, Anna, additional, Christensen, Jacob Haaber, additional, Hess, Brian, additional, Tilly, Herve, additional, Cordoba, Raul, additional, Lewis, David John, additional, Okada, Craig, additional, Hutchings, Martin, additional, Clausen, Michael Roost, additional, Vitolo, Umberto, additional, Cochrane, Tara, additional, Leppä, Sirpa, additional, Chamuleau, Martine E.D., additional, Conlon, Rebekah, additional, Favaro, Elena, additional, Favaro, Diana, additional, Altıntaş, Işıl, additional, Liu, Yan, additional, and Thieblemont, Catherine, additional

Published
2024
Full Text
View/download PDF

8. IBCL-474 Epcoritamab + R2 Regimen and Responses in Patients With High-Risk Follicular Lymphoma, Regardless of POD24 Status

Author

Merryman, Reid W., primary, Belada, David, additional, Sureda, Anna, additional, Leppä, Sirpa, additional, Vermaat, Joost S.P., additional, Holte, Harald, additional, Hutchings, Martin, additional, Lugtenburg, Pieternella, additional, de Vos, Sven, additional, Abrisqueta, Pau, additional, Nijland, Marcel, additional, Christensen, Jacob Haaber, additional, Wahlin, Björn E., additional, Linton, Kim M., additional, Wang, Liwei, additional, Abbas, Aqeel, additional, Rana, Ali, additional, Quadri, Syed, additional, and Falchi, Lorenzo, additional

Published
2023
Full Text
View/download PDF

9. POSTER: IBCL-474 Epcoritamab + R2 Regimen and Responses in Patients With High-Risk Follicular Lymphoma, Regardless of POD24 Status

Author

Merryman, Reid W., primary, Belada, David, additional, Sureda, Anna, additional, Leppä, Sirpa, additional, Vermaat, Joost S.P., additional, Holte, Harald, additional, Hutchings, Martin, additional, Lugtenburg, Pieternella, additional, de Vos, Sven, additional, Abrisqueta, Pau, additional, Nijland, Marcel, additional, Christensen, Jacob Haaber, additional, Wahlin, Björn E., additional, Linton, Kim M., additional, Wang, Liwei, additional, Abbas, Aqeel, additional, Rana, Ali, additional, Quadri, Syed, additional, and Falchi, Lorenzo, additional

Published
2023
Full Text
View/download PDF

11. S222: EPCORITAMAB WITH RITUXIMAB + LENALIDOMIDE (R2) PROVIDES DURABLE RESPONSES IN PATIENTS WITH HIGH-RISK FOLLICULAR LYMPHOMA, REGARDLESS OF POD24 STATUS

Author

Sureda, Anna, primary, Falchi, Lorenzo, additional, Leppa, Sirpa, additional, Vermaat, Joost, additional, Holte, Harald, additional, Hutchings, Martin, additional, Lugtenburg, Pieternella, additional, de Vos, Sven, additional, Abrisqueta, Pau, additional, Nijland, Marcel, additional, Merryman, Reid W., additional, Christensen, Jacob Haaber, additional, Wahlin, Bjorn, additional, Linton, Kim, additional, Wang, Liwei, additional, Abbas, Aqeel, additional, Rana, Ali, additional, Quadri, Syed, additional, and Belada, David, additional

Published
2023
Full Text
View/download PDF

12. Age-Based Validation of the Advanced-Stage Hodgkin Lymphoma International Prognostic Index (A-HIPI) in a Real-World Danish Study: Suboptimal Performance in Older Patients

Author

Rask Kragh Jørgensen, Rasmus, Eloranta, Sandra, Christensen, Jacob Haaber, Hutchings, Martin, Dahl-soerensen, Rasmus Bo, Kamper, Peter, Evens, Andrew M, Maurer, Matthew J., Parsons, Susan K, Rodday, Angie Mae, Upshaw, Jenica, El-galaly, Tarec Christoffer Christoffer, Jakobsen, Lasse Hjort, Rask Kragh Jørgensen, Rasmus, Eloranta, Sandra, Christensen, Jacob Haaber, Hutchings, Martin, Dahl-soerensen, Rasmus Bo, Kamper, Peter, Evens, Andrew M, Maurer, Matthew J., Parsons, Susan K, Rodday, Angie Mae, Upshaw, Jenica, El-galaly, Tarec Christoffer Christoffer, and Jakobsen, Lasse Hjort

Abstract

Purpose: Improved predictive tools are desired in classic Hodgkin lymphoma (cHL) to improve prognostication and to better risk stratify patients (pts) for clinical trials. In younger pts who tolerate intensive therapies, focus has been on limiting late treatment toxicity through risk-adapted, PET-guided treatment strategy. In older pts, acute treatment toxicities are limiting factors for optimal disease control. Due to these fundamental differences, predictive tools may perform differently in younger and older pts. In particular, tools developed in younger pts may be suboptimal in older populations and vice versa. The primary objective of this study was to assess the performance of the A-HIPI (development was limited to 18-65 years of age) against the international prognostic score (IPS) for modelling overall survival (OS) and progression-free survival (PFS) in younger and older pts with cHL.

Published
2023

13. Long-Term Cause-Specific Mortality in Hodgkin Lymphoma Patients - a Nationwide Danish Cohort Study

Author

Rossetti, Sara, Juul, Sidsel Jacobsen, Eriksson, Frank, Warming, Peder Emil, Glinge, Charlotte, El-galaly, Tarec Christoffer Christoffer, Christensen, Jacob Haaber, Kamper, Peter, Brown, Peter De Nully, Maraldo, Maja, Tfelt-hansen, Jacob, Hutchings, Martin, Rossetti, Sara, Juul, Sidsel Jacobsen, Eriksson, Frank, Warming, Peder Emil, Glinge, Charlotte, El-galaly, Tarec Christoffer Christoffer, Christensen, Jacob Haaber, Kamper, Peter, Brown, Peter De Nully, Maraldo, Maja, Tfelt-hansen, Jacob, and Hutchings, Martin

Abstract

Introduction: The documented treatment-induced excess mortality in Hodgkin lymphoma (HL) has led to significant changes in treatment regimens aimed at maintaining efficacy while reducing toxicity. These modifications include the replacement of alkylator-based regimens with anthracycline-based combinations and the adoption of highly conformal radiotherapy. Danish and Nordic radiation oncologists were pioneers in implementing these changes nationwide 10-15 years earlier than most other nations. These early adaptations make Danish HL data uniquely valuable for assessing long-term mortality in a cohort where modern treatment regimens have been implemented nationwide throughout the entire study period. The impact of these treatment modifications on mortality risk in HL survivors remains unclear, therefore, this study aims to assess cause-specific mortality among HL patients treated with contemporary strategies. Methods: This nationwide, unselected study included all HL patients in Denmark aged 15-40 years at diagnosis and treated between 1995 and 2015. Patients were followed from diagnosis until emigration, death, or the study end. HL cases were identified through meticulous individual record reviews of medical records, national registries, and pathology data. Disease-specific death due to HL was the primary outcome, with other cause-specific mortality as a competing risk. Cox proportional hazard models assessed factors influencing overall survival and cause-specific survival. A landmark analysis was conducted to compare the risk of death between the study population and the national background population. Results: Among 1,348 included HL patients, 66.5% had Ann Arbor stage I-II at the time of diagnosis. During 18,731 person-years of follow-up, 139 deaths occurred, resulting in a 5-year overall survival rate of 94.6% (95% CI 93.4-95.8). Factors associated with higher overall mortality risk included older age, advanced disease stage at diagnosis, earlier

Published
2023

14. Subcutaneous Epcoritamab with Rituximab + Lenalidomide in Patients with Relapsed or Refractory Follicular Lymphoma:Phase 1/2 Trial Update

Author

Falchi, Lorenzo, primary, Abrisqueta, Pau, additional, Nijland, Marcel, additional, Leppä, Sirpa, additional, Hutchings, Martin, additional, Holte, Harald, additional, Merryman, Reid W, additional, Lugtenburg, Pieternella, additional, de Vos, Sven, additional, Cheah, Chan Y., additional, Christensen, Jacob Haaber, additional, Arcaini, Luca, additional, Drott, Kristina, additional, Hellström, Mats, additional, Leslie, Lori A., additional, Vitolo, Umberto, additional, Rana, Ali, additional, Abbas, Aqeel, additional, Wang, Liwei, additional, Dinh, Minh, additional, and Belada, David, additional

Published
2022
Full Text
View/download PDF

15. Subcutaneous Epcoritamab in Patients with Richter's Syndrome: Early Results from Phase 1b/2 Trial (EPCORE CLL-1)

Author

Kater, Arnon P., primary, Ye, J Christine, additional, Sandoval-Sus, Jose, additional, Bellido, Mar, additional, Christensen, Jacob Haaber, additional, Mato, Anthony R., additional, Janssens, Ann, additional, Oki, Toshihiko, additional, Hoehn, Daniela, additional, Rios, Marcia, additional, Kuznetsova, Alexandra, additional, Valentin, Rebecca, additional, and Eradat, Herbert, additional

Published
2022
Full Text
View/download PDF

16. Venetoclax, Lenalidomide and Rituximab for Patients with Relapsed or Refractory Mantle Cell Lymphoma - the Nordic Lymphoma Group NLG-MCL7 (VALERIA) Phase Ib-II Trial

Author

Jerkeman, Mats, primary, Kolstad, Arne, additional, Hutchings, Martin, additional, Pasanen, Annika, additional, Meriranta, Leo, additional, Niemann, Carsten Utoft, additional, Rask Kragh Jørgensen, Rasmus, additional, El-Galaly, Tarec Christoffer Christoffer, additional, Riise, Jon, additional, Leppä, Sirpa, additional, Christensen, Jacob Haaber, additional, Wader, Karin Fahl, additional, and Glimelius, Ingrid, additional

Published
2022
Full Text
View/download PDF

17. Subcutaneous Epcoritamab in Combination with Rituximab + Lenalidomide (R2) for First-Line Treatment of Follicular Lymphoma: Initial Results from Phase 1/2 Trial

Author

Falchi, Lorenzo, primary, Leslie, Lori A., additional, Belada, David, additional, Kopeckova, Katerina, additional, Offner, Fritz, additional, Brody, Joshua, additional, Canales, Miguel, additional, Martín García-Sancho, Alejandro, additional, Nijland, Marcel, additional, Andersson, P-O, additional, Awan, Farrukh T., additional, Christensen, Jacob Haaber, additional, Drott, Kristina, additional, Hellström, Mats, additional, Lewerin, Catharina, additional, Narkhede, Mayur, additional, Snauwaert, Sylvia, additional, Wahlin, Björn E, additional, Rana, Ali, additional, Abbas, Aqeel, additional, Wang, Liwei, additional, Dinh, Minh, additional, Vermaat, Joost S.P., additional, and Abrisqueta, Pau, additional

Published
2022
Full Text
View/download PDF

18. P074: Long-Term Cause-Specific Mortality in Hodgkin Lymphoma Patients – A Nationwide Danish Cohort Study

Author

Rossetti, Sára, primary, Juul, Sidsel Jacobsen, additional, Eriksson, Frank, additional, Warming, Peder Emil, additional, Glinge, Charlotte, additional, El-Galaly, Tarec Christoffer, additional, Christensen, Jacob Haaber, additional, Kamper, Peter, additional, De Nully Brown, Peter, additional, Maraldo, Maja Vestmø, additional, Tfelt-Hansen, Jacob, additional, and Hutchings, Martin, additional

Published
2022
Full Text
View/download PDF

19. Subcutaneous epcoritamab with rituximab + lenalidomide (R2) in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): Update from phase 1/2 trial.

Author

Falchi, Lorenzo, primary, Leppä, Sirpa, additional, Wahlin, Bjorn E., additional, Nijland, Marcel, additional, Christensen, Jacob Haaber, additional, De Vos, Sven, additional, Holte, Harald, additional, Linton, Kim M., additional, Abbas, Aqeel, additional, Wang, Liwei, additional, Dinh, Minh, additional, Elliott, Brian, additional, and Belada, David, additional

Published
2022
Full Text
View/download PDF

20. Role of Stem Cell Transplant in CD30+ PTCL Following Frontline Brentuximab Vedotin Plus CHP or CHOP in ECHELON-2.

Author

Savage, Kerry J, Horwitz, Steven M, Advani, Ranjana, Christensen, Jacob Haaber, Domingo-Domenech, Eva, Rossi, Giuseppe, Morschhauser, Franck, Alpdogan, Onder, Suh, Cheolwon, Tobinai, Kensei, Shustov, Andrei, Trneny, Marek, Yuen, Sam, Zinzani, Pier Luigi, Trümper, Lorenz, Ilidge, Tim, O'Connor, Owen A, Pro, Barbara, Miao, Harry, Bunn, Veronica, Fenton, Keenan, Fanale, Michelle, Puhlmann, Markus, Iyer, Swaminathan, Savage, Kerry J, Horwitz, Steven M, Advani, Ranjana, Christensen, Jacob Haaber, Domingo-Domenech, Eva, Rossi, Giuseppe, Morschhauser, Franck, Alpdogan, Onder, Suh, Cheolwon, Tobinai, Kensei, Shustov, Andrei, Trneny, Marek, Yuen, Sam, Zinzani, Pier Luigi, Trümper, Lorenz, Ilidge, Tim, O'Connor, Owen A, Pro, Barbara, Miao, Harry, Bunn, Veronica, Fenton, Keenan, Fanale, Michelle, Puhlmann, Markus, and Iyer, Swaminathan

Abstract

Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of aggressive non-Hodgkin lymphomas, the majority of which have high relapse rates following standard therapy. Despite use of consolidative stem cell transplant (SCT) following frontline therapy, there remains no consensus on its utility. The double-blind randomized phase 3 ECHELON-2 study (#NCT01777152; clinicaltrials.gov) demonstrated improved progression-free survival (PFS) and overall survival with frontline brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone (A+CHP). Herein, we conducted an exploratory subgroups analysis of the impact of consolidative SCT on PFS in patients with previously untreated CD30+ PTCL (ALK- anaplastic large cell lymphoma [ALCL] and non-ALCL) who were in complete response (CR) after frontline treatment with A+CHP or cyclophosphamide, doxorubicin, vincristine, and prednisone. Median PFS follow-up was 47.57 months. The PFS hazard ratio was 0.36, equating to a 64% reduction in the risk of a PFS event in patients who underwent SCT. The median PFS in patients who underwent SCT was not reached, vs 55.66 months in patients who did not undergo SCT. PFS results favored the use of SCT in both ALK- ALCL and non-ALCL subgroups. These data support the consideration of consolidative SCT in patients with CD30+PTCL who achieve CR following treatment with A+CHP.

Published
2022

21. Late recurrence of lymphoid malignancies after initial treatment for Hodgkin lymphoma – A study from the Danish Lymphoma Registry

Author

Andersen, Maja Dam, primary, Hamilton‐Dutoit, Stephen, additional, Modvig, Lena, additional, Vase, Maja, additional, Christiansen, Ilse, additional, Christensen, Jacob Haaber, additional, Dahl‐Sørensen, Rasmus Bo, additional, Stoltenberg, Danny, additional, Kamper, Peter, additional, and d'Amore, Francesco, additional

Published
2022
Full Text
View/download PDF

22. The ECHELON-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A plus CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma

Author

Iyer, Swaminathan, Truemper, Lorenz, O'Connor, Owen A., Pro, Barbara, Illidge, Tim, Advani, Ranjana, Bartlett, Nancy L., Christensen, Jacob Haaber, Morschhauser, Franck, Domingo-Domenech, Eva, Rossi, Giuseppe, Kim, Won Seog, Feldman, Tatyana, Menne, Tobias, Belada, David, Illes, Arpad, Tobinai, Kensei, Tsukasaki, Kunihiro, Yeh, Su-Peng, Shustov, Andrei, Huettmann, Andreas, Savage, Kerry J., Yuen, Sam, Zinzani, Pier Luigi, Miao, Harry, Bunn, Veronica, Fenton, Keenan, Fanale, Michelle, Puhlmann, Markus, and Horwitz, Steven

Subjects
TCL, A plus CHP, BV, T-cell lymphoma, CHOP
Published
2021
Full Text
View/download PDF

23. Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Mantle Cell Lymphoma Not Previously Treated with a BTK Inhibitor: Primary Analysis from a Phase 2 Study (CITADEL-205)

Author

Mehta, Amitkumar, primary, Trněný, Marek, additional, Walewski, Jan, additional, Ribrag, Vincent, additional, Dartigeas, Caroline, additional, Christensen, Jacob Haaber, additional, Pane, Fabrizio, additional, Rodriguez, Guillermo, additional, Taszner, Michal, additional, Venugopal, Parameswaran, additional, Zilioli, Vittorio Ruggero, additional, Zheng, Fred, additional, DeMarini, Douglas J, additional, Jiang, Wei, additional, and Zinzani, Pier Luigi Luigi, additional

Published
2021
Full Text
View/download PDF

24. Subcutaneous Epcoritamab in Combination with R-CHOP in Patients with Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma: Preliminary Results from a Phase 1/2 Trial

Author

Belada, David, primary, Christensen, Jacob Haaber, additional, Drott, Kristina, additional, Snauwaert, Sylvia, additional, Brody, Joshua, additional, Narkhede, Mayur, additional, Offner, Fritz, additional, Elliot, Brian, additional, Liu, Tracy, additional, Cota Stirner, Mariana, additional, Abbas, Aqeel, additional, Falchi, Lorenzo, additional, and Clausen, Michael Roost, additional

Published
2021
Full Text
View/download PDF

26. TCL-150: The ECHELON-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma

Author

Iyer, Swaminathan, primary, Trümper, Lorenz, additional, O’Connor, Owen A., additional, Pro, Barbara, additional, Illidge, Tim, additional, Advani, Ranjana, additional, Bartlett, Nancy L., additional, Christensen, Jacob Haaber, additional, Morschhauser, Franck, additional, Domingo-Domenech, Eva, additional, Rossi, Giuseppe, additional, Kim, Won Seog, additional, Feldman, Tatyana, additional, Menne, Tobias, additional, Belada, David, additional, Illès, Árpád, additional, Tobinai, Kensei, additional, Tsukasaki, Kunihiro, additional, Yeh, Su-Peng, additional, Shustov, Andrei, additional, Hüttmann, Andreas, additional, Savage, Kerry J., additional, Yuen, Sam, additional, Zinzani, Pier Luigi, additional, Miao, Harry, additional, Bunn, Veronica, additional, Fenton, Keenan, additional, Fanale, Michelle, additional, Puhlmann, Markus, additional, and Horwitz, Steven, additional

Published
2021
Full Text
View/download PDF

27. Oral Abstract: TCL-150: The ECHELON-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma

Author

Iyer, Swaminathan, primary, Trümper, Lorenz, additional, O’Connor, Owen A., additional, Pro, Barbara, additional, Illidge, Tim, additional, Advani, Ranjana, additional, Bartlett, Nancy L., additional, Christensen, Jacob Haaber, additional, Morschhauser, Franck, additional, Domingo-Domenech, Eva, additional, Rossi, Giuseppe, additional, Kim, Won Seog, additional, Feldman, Tatyana, additional, Menne, Tobias, additional, Belada, David, additional, Illès, Árpád, additional, Tobinai, Kensei, additional, Tsukasaki, Kunihiro, additional, Yeh, Su-Peng, additional, Shustov, Andrei, additional, Hüttmann, Andreas, additional, Savage, Kerry J., additional, Yuen, Sam, additional, Zinzani, Pier Luigi, additional, Miao, Harry, additional, Bunn, Veronica, additional, Fenton, Keenan, additional, Fanale, Michelle, additional, Puhlmann, Markus, additional, and Horwitz, Steven, additional

Published
2021
Full Text
View/download PDF

28. Poster: TCL-150: The ECHELON-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma

Author

Iyer, Swaminathan, primary, Trümper, Lorenz, additional, O’Connor, Owen A., additional, Pro, Barbara, additional, Illidge, Tim, additional, Advani, Ranjana, additional, Bartlett, Nancy L., additional, Christensen, Jacob Haaber, additional, Morschhauser, Franck, additional, Domingo-Domenech, Eva, additional, Rossi, Giuseppe, additional, Kim, Won Seog, additional, Feldman, Tatyana, additional, Menne, Tobias, additional, Belada, David, additional, Illès, Árpád, additional, Tobinai, Kensei, additional, Tsukasaki, Kunihiro, additional, Yeh, Su-Peng, additional, Shustov, Andrei, additional, Hüttmann, Andreas, additional, Savage, Kerry J., additional, Yuen, Sam, additional, Zinzani, Pier Luigi, additional, Miao, Harry, additional, Bunn, Veronica, additional, Fenton, Keenan, additional, Fanale, Michelle, additional, Puhlmann, Markus, additional, and Horwitz, Steven, additional

Published
2021
Full Text
View/download PDF

29. ECHELON-2 (NCT01777152), a randomized, double-blind, phase 3 study of brentuximab vedotin plus cyclophosphamide doxorubicin and prednisone versus cyclophosphamide, doxorubicin, vincristine and prednisone in previously untreated patients with CD30-positive peripheral T-cell lymphoma: 5-year results

Author

Illidge, Timothy, Horwitz, Steven M., O'Connor, Owen A., Pro, Barbara, Iyer, Swami P., Advani, Ranjana, Bartlett, Nancy L., Christensen, Jacob Haaber, Morschhauser, Franck, Domingo-Domenech, Eva, Rossi, Giuseppe, Kim, Won Seog, Feldman, Tatyana A., Menne, Tobias, Belada, David, Illes, Arpad, Tobinai, Kensei, Tsukasaki, Kunihiro, Yeh, Su-Peng, Huettmann, Andreas, Savage, Kerry J., Yuen, Sam, Zinzani, Pier Luigi, Miao, Harry, Bunn, Veronica, Fenton, Keenan, Fanale, Michelle A., Puhlmann, Markus, and Truemper, Lorenz

Published
2021
Full Text
View/download PDF

30. PET4 Response As an Independent Predictor of Long-Term Outcomes in ECHELON2 (A+CHP Vs. CHOP) in CD30+PTCL

Author

Iyer, Swami P., Mehta-Shah, Neha, Advani, Ranjana H., Bartlett, Nancy L., Christensen, Jacob Haaber, Morschhauser, Frank, Domingo Domenech, EVA, Pagani, Chiara, Kim, Won Seog, Alpdogan, Onder, Suh, Cheolwon, Feldman, Tatyana, Tilly, Hervé, Zinzani, Pier Luigi, Rambaldi, Alessandro, Belada, David, Mayer, Jiri, Choi, Ilseung, Cheong, June-Won, Jain, Shweta, Keenan, Fenton, Fanale, Michelle A., Savage, Kerry J., and Horwitz, Steven M.

Published
2023
Full Text
View/download PDF

31. Epcoritamab SC Monotherapy Leads to Deep and Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma: First Data Disclosure from the Epcore NHL-1 Follicular Lymphoma Dose-Expansion Cohort

Author

Linton, Kim, Jurczak, Wojciech, Lugtenburg, Pieternella, Gyan, Emmanuel, Sureda Balari, Anna Maria, Christensen, Jacob Haaber, Hess, Brian, Tilly, Hervé, Cordoba, Raul, Lewis, David, Okada, Craig, Hutchings, Martin, Clausen, Michael Roost, Vitolo, Umberto, Cochrane, Tara, Leppa, Sirpa, Chamuleau, Martine E.D., Conlon, Rebekah, Favaro, Elena, Gernhardt, Diana, Altintas, Isil, Liu, Yan, and Thieblemont, Catherine

Published
2023
Full Text
View/download PDF

32. The Echelon-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma

Author

Horwitz, Steven M., O'Connor, Owen A., Pro, Barbara, Illidge, Tim, Iyer, Swami P., Advani, Ranjana, Bartlett, Nancy L., Christensen, Jacob Haaber, Morschhauser, Franck, Domingo-Domenech, Eva, Rossi, Giuseppe, Kim, Won Seog, Feldman, Tatyana A., Menne, Tobias, Belada, David, Illés, Árpád, Tobinai, Kensei, Tsukasaki, Kunihiro, Yeh, Su-Peng, Shustov, Andrei R, Hüttmann, Andreas, Savage, Kerry J., Yuen, Sam, Zinzani, Pier Luigi, Miao, Harry, Bunn, Veronica, Fenton, Keenan, Fanale, Michelle A., Puhlmann, Markus, and Truemper, Lorenz

Published
2020
Full Text
View/download PDF

33. Role of stem cell transplant in CD30+PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2

Author

Savage, Kerry J., Horwitz, Steven M., Advani, Ranjana, Christensen, Jacob Haaber, Domingo-Domenech, Eva, Rossi, Giuseppe, Morschhauser, Franck, Alpdogan, Onder, Suh, Cheolwon, Tobinai, Kensei, Shustov, Andrei, Trneny, Marek, Yuen, Sam, Zinzani, Pier Luigi, Trümper, Lorenz, Ilidge, Tim, O’Connor, Owen A., Pro, Barbara, Miao, Harry, Bunn, Veronica, Fenton, Keenan, Fanale, Michelle, Puhlmann, Markus, and Iyer, Swaminathan

Abstract

•Consolidative SCT should be considered in patients with CD30+PTCL in a CR following frontline treatment with A+CHP.•Further studies are needed to establish the benefits of consolidative SCT in this setting.

Published
2022
Full Text
View/download PDF

34. Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Mantle Cell Lymphoma Not Previously Treated with a BTK Inhibitor (CITADEL-205)

Author

Mehta, Amitkumar, primary, Trněný, Marek, additional, Walewski, Jan, additional, Ribrag, Vincent, additional, Dartigeas, Caroline, additional, Christensen, Jacob Haaber, additional, Pane, Fabrizio, additional, Rodríguez, Guillermo, additional, Taszner, Michal, additional, Venugopal, Parameswaran, additional, Zilioli, Vittorio Ruggero, additional, Zheng, Fred, additional, DeMarini, Douglas J, additional, Jiang, Wei, additional, and Zinzani, Pier Luigi, additional

Published
2020
Full Text
View/download PDF

35. The ECHELON-2 Trial: Results of a Randomized, Double-Blind, Active-Controlled, Global Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Previously-Untreated Subjects with CD30-expressing Peripheral T-Cell Lymphomas

Author

Illidge, Tim, Pro, Barbara, Trumper, Lorenz, O'Connor, Owen A, Advani, Ranjana, Iyer, Swaminathan, Bartlett, Nancy L, Christensen, Jacob Haaber, Morschhauser, Frank, Domingo-Domenech, Eva, Rossi, Giuseppe, Kim, Won Seog, Feldman, Tatyana, Lennard, Anne, Belada, David, Illés, Árpád, Tobinai, Kensei, Tsukasaki, Kunihiro, Yeh, Su-Peng, Zinzani, Pier-Luigi, Little, Meredith, Manley, Thomas, Rao, Shangbang, Fanale, Michelle, and Horwitz, Steven

Published
2019

37. Clinical prognostic scores are poor predictors of overall survival in various types of malignant lymphomas

Author

Biccler, Jorne Lionel, El-Galaly, Tarec Christoffer, Bøgsted, Martin, Jørgensen, Judit, de Nully Brown, Peter, Poulsen, Christian Bjørn, Starklint, Jørn, Juul, Maja Bech, Christensen, Jacob Haaber, Josefsson, Pär, Dessau, Andriette, Jakobsen, Lasse Hjort, Biccler, Jorne Lionel, El-Galaly, Tarec Christoffer, Bøgsted, Martin, Jørgensen, Judit, de Nully Brown, Peter, Poulsen, Christian Bjørn, Starklint, Jørn, Juul, Maja Bech, Christensen, Jacob Haaber, Josefsson, Pär, Dessau, Andriette, and Jakobsen, Lasse Hjort

Published
2019

39. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

Author

Horwitz, Steven, primary, O'Connor, Owen A, additional, Pro, Barbara, additional, Illidge, Tim, additional, Fanale, Michelle, additional, Advani, Ranjana, additional, Bartlett, Nancy L, additional, Christensen, Jacob Haaber, additional, Morschhauser, Franck, additional, Domingo-Domenech, Eva, additional, Rossi, Giuseppe, additional, Kim, Won Seog, additional, Feldman, Tatyana, additional, Lennard, Anne, additional, Belada, David, additional, Illés, Árpád, additional, Tobinai, Kensei, additional, Tsukasaki, Kunihiro, additional, Yeh, Su-Peng, additional, Shustov, Andrei, additional, Hüttmann, Andreas, additional, Savage, Kerry J, additional, Yuen, Sam, additional, Iyer, Swaminathan, additional, Zinzani, Pier Luigi, additional, Hua, Zhaowei, additional, Little, Meredith, additional, Rao, Shangbang, additional, Woolery, Joseph, additional, Manley, Thomas, additional, Trümper, Lorenz, additional, Aboulafia, David, additional, Alpdogan, Onder, additional, Ando, Kiyoshi, additional, Arcaini, Luca, additional, Baldini, Luca, additional, Bellam, Naresh, additional, Bartlett, Nancy, additional, Yehuda, Dina Ben, additional, Benedetti, Fabio, additional, Borchman, Peter, additional, Bordessoule, Dominique, additional, Brice, Pauline, additional, Briones, Javier, additional, Caballero, Dolores, additional, Carella, Angelo Michele, additional, Chang, Hung, additional, Cheong, June Weon, additional, Cho, Seok-Goo, additional, Choi, Ilseung, additional, Choquet, Sylvain, additional, Colita, Andrei, additional, Congui, Angela Giovanna, additional, D'amore, Francesco, additional, Dang, Nam, additional, Davison, Kelly, additional, de Guibert, Sophie, additional, Brown, Peter de Nully, additional, Delwail, Vincent, additional, Demeter, Judit, additional, di Raimondo, Francesco, additional, Do, Young Rok, additional, Domingo, Eva, additional, Douvas, Michael, additional, Dreyling, Martin, additional, Ernst, Thomas, additional, Fay, Keith, additional, Ferrero, Silvia Fernandez, additional, Flinn, Ian Winchester, additional, Forero-Torres, Andres, additional, Fox, Christopher, additional, Friedberg, Jonathan, additional, Fukuhara, Noriko, additional, Garcia-Marco, Jose, additional, Cruz, Jorge Gayoso, additional, Codina, Jose Gomez, additional, Gressin, Remy, additional, Grigg, Andrew, additional, Gurion, Ronit, additional, Haioun, Corinne, additional, Hajek, Roman, additional, Hanel, Mathias, additional, Hatake, Kiyohiko, additional, Hensen, Robert, additional, Horowitz, Netanel, additional, Horwitz, Steven, additional, Huttmann, Andreas, additional, Illes, Arpad, additional, Ishizawa, Kenichi, additional, Islas-Ohlmayer, Miguel, additional, Jacobsen, Eric, additional, Janakiram, Murali, additional, Jurczak, Wojciech, additional, Kaminski, Mark, additional, Kato, Koji, additional, Kirgner, Ilya, additional, Kuo, Ching-Yuan, additional, Lazaroiu, Mihaela Cornelia, additional, Du, Katell Le, additional, Lee, Jong-Seok, additional, LeGouill, Steven, additional, LaRosee, Paul, additional, Levi, Itai, additional, Link, Brian, additional, Maisonneuve, Herve, additional, Maruyama, Dai, additional, Mayer, Jiri, additional, McCarty, John, additional, McKay, Pam, additional, Minami, Yosuke, additional, Mocikova, Heidi, additional, Morra, Enrica, additional, Munoz, Javier, additional, Nagai, Hirokazu, additional, O'Connor, Owen, additional, Opat, Stephen, additional, Pettengell, Ruth, additional, Pezzutto, Antonio, additional, Pfreundschuh, Michael, additional, Pluta, Andrzej, additional, Porcu, PierLuigi, additional, Quach, Hang, additional, Rambaldi, Alessandro, additional, Renwick, William, additional, Reyes, Ruben, additional, Izquierdo, Antonia Rodriguez, additional, Ruan, Jia, additional, Rusconi, Chiara, additional, Salles, Gilles, additional, Santoro, Armando, additional, Sarriera, Jose, additional, Savage, Kerry, additional, Shibayama, Hirohiko, additional, Suh, Cheolwon, additional, Sureda, Anna, additional, Tanimoto, Mitsune, additional, Taniwaki, Masafumi, additional, Tilly, Herve, additional, Trneny, Marek, additional, Trumper, Lorenz, additional, Tsukamoto, Norifumi, additional, Vitolo, Umberto, additional, Walewski, Jan, additional, Weidmann, Eckhart, additional, Wilhelm, Martin, additional, Witzens-Harig, Mathias, additional, Yacoub, Abdulraheem, additional, Yamamoto, Kazuhito, additional, Yoon, Sung-Soo, additional, Yun, Hwan Jung, additional, and Zain, Jasmine, additional

Published
2019
Full Text
View/download PDF

40. Malignt Lymfom og CLL:National årsrapport 2016

Author

Brown, Peter de Nully, Jensen, Paw, Jørgensen, Judit, Pedersen, Per, Christensen, Jacob Haaber, Poulsen, Christian B, Josefsson, Pär, Pedersen, Michael, and Starklint, Jørn

Published
2017

41. The ECHELON-2 Trial: Results of a Randomized, Double-Blind, Active-Controlled Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas

Author

Horwitz, Steven M., primary, O'Connor, Owen A., additional, Pro, Barbara, additional, Illidge, Tim M., additional, Fanale, Michelle A., additional, Advani, Ranjana H, additional, Bartlett, Nancy L., additional, Christensen, Jacob Haaber, additional, Morschhauser, Franck, additional, Domingo-Domenech, Eva, additional, Rossi, Giuseppe, additional, Kim, Won Seog, additional, Feldman, Tatyana A., additional, Lennard, Anne, additional, Belada, David, additional, Illés, Árpád, additional, Tobinai, Kensei, additional, Tsukasaki, Kunihiro, additional, Yeh, Su-Peng, additional, Shustov, Andrei R., additional, Hüttmann, Andreas, additional, Savage, Kerry J, additional, Yuen, Sam, additional, Zinzani, Pier Luigi, additional, Hua, Zhaowei, additional, Little, Meredith, additional, Rao, Shangbang, additional, Woolery, Joseph, additional, Manley, Thomas, additional, and Trümper, Lorenz, additional

Published
2018
Full Text
View/download PDF

42. Clinical prognostic scores are poor predictors of overall survival in various types of malignant lymphomas

Author

Biccler, Jorne Lionel, primary, El-Galaly, Tarec Christoffer, additional, Bøgsted, Martin, additional, Jørgensen, Judit, additional, de Nully Brown, Peter, additional, Poulsen, Christian Bjørn, additional, Starklint, Jørn, additional, Juul, Maja Bech, additional, Christensen, Jacob Haaber, additional, Josefsson, Pär, additional, Dessau, Andriette, additional, and Jakobsen, Lasse Hjort, additional

Published
2018
Full Text
View/download PDF

43. Phase II study of single-agent copanlisib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

Author

Lenz, Georg, primary, Hawkes, Eliza, additional, Verhoef, Gregor, additional, Haioun, Corinne, additional, Thye, Lim Soon, additional, Heo, Dae Seog, additional, Ardeshna, Kirit, additional, Chong, Geoffrey, additional, Christensen, Jacob Haaber, additional, Shi, Vivian, additional, Lippert, Susanne, additional, Hiemeyer, Florian, additional, Piraino, Paolo, additional, Pena, Carol Elaine, additional, Buvaylo, Viktoriya, additional, Childs, Barrett H., additional, Gorbatchevsky, Igor, additional, and Salles, Gilles A., additional

Published
2017
Full Text
View/download PDF

44. Rituximab Maintenance after First Line Immunochemotherapy Improves Overall Survival in Patients with Follicular Lymphoma

Author

Vilmar, Adam, primary, Arboe, Bente, additional, Josefsson, Par, additional, Poulsen, Christian, additional, Christensen, Jacob Haaber, additional, Jørgensen, Judit, additional, Jensen, Paw, additional, Starklint, Jørn, additional, Pedersen, Per Troellund, additional, Pedersen, Michael, additional, and Brown, Peter de Nully, additional

Published
2016
Full Text
View/download PDF

46. The Danish National Lymphoma Registry: Coverage and Data Quality

Author

Arboe, Bente, primary, El-Galaly, Tarec Christoffer, additional, Clausen, Michael Roost, additional, Munksgaard, Peter Svenssen, additional, Stoltenberg, Danny, additional, Nygaard, Mette Kathrine, additional, Klausen, Tobias Wirenfeldt, additional, Christensen, Jacob Haaber, additional, Gørløv, Jette Sønderskov, additional, and Brown, Peter de Nully, additional

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results